FLASCO / Recent Advances and Real-World Implications in Medical Oncology: A Daylong Multitumor Educational Symposium in Partnership with the American Oncology Network (Virtual and In-Person)

Event Details

Start: 6 August 2022 12:00 pm EDT
End: 6 August 2022 7:30 pm EDT

Opening Remarks | 9:00 AM – 9:05 AM PT (12:00 PM – 12:05 PM ET)

Module 1
Breast Cancer | 9:05 AM – 10:05 AM PT (12:05 PM – 1:05 PM ET)

Feasibility of chemotherapy de-escalation with dual HER2 blockade for patients with localized breast cancer
Adjuvant T-DM1 for patients with residual disease after neoadjuvant therapy
Neratinib as extended-adjuvant therapy; improvement in rates of CNS recurrence after long-term follow-up in the Phase III ExteNET study
Optimizing the use of postadjuvant neratinib; available data with and rationale for a dose-escalation strategy
Ongoing clinical trials investigating novel HER2-targeted therapy for HER2-positive localized breast cancer (eg, DESTINY-Breast05, CompassHER2 RD, MARGOT)
Published data from the pivotal HER2CLIMB, DESTINY-Breast01 and NALA studies of tucatinib/trastuzumab/capecitabine, trastuzumab deruxtecan (T-DXd) and neratinib/capecitabine, respectively, for HER2-positive metastatic breast cancer (mBC)
Integration of tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine into therapy for patients with and without brain metastases
Updated results from the Phase III DESTINY-Breast03 trial evaluating T-DXd versus T-DM1 for previously treated HER2-positive mBC
Findings from the Phase III DESTINY-Breast04 trial evaluating T-DXd versus treatment of physician’s choice for patients with previously treated HER2-low unresectable and/or metastatic breast cancer
Ongoing clinical studies evaluating novel HER2-targeted combination strategies for HER2-positive mBC (eg, HER2CLIMB-02, DESTINY-Breast07)
Major findings from the Phase III RxPONDER trial evaluating the role of chemotherapy for patients with ER-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score^® of ≤25
Key outcomes observed with abemaciclib added to standard adjuvant hormonal therapy for patients with ER-positive, HER2-negative breast cancer in the Phase III monarchE trial; FDA approval and current role of adjuvant abemaciclib
Other ongoing studies evaluating CDK4/6 inhibitors as neoadjuvant or adjuvant therapy
Long-term follow-up data with CDK4/6 inhibitors for patients with ER-positive mBC
Major research findings with alpelisib/fulvestrant for patients with ER-positive mBC and a PIK3CA mutation
Optimal prevention and management strategies for alpelisib-related toxicities
Findings from the FAKTION trial evaluating fulvestrant with capivasertib versus fulvestrant with placebo after relapse or progression on an aromatase inhibitor for ER-positive mBC
Key outcomes of the Phase III OlympiA trial assessing adjuvant olaparib for patients with germline BRCA1/2 mutations and high-risk, HER2-negative breast cancer; current and potential role of adjuvant olaparib
Available data from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized triple-negative breast cancer (TNBC)
Phase III data sets evaluating anti-PD-1/PD-L1 antibodies with chemotherapy for patients with previously untreated PD-L1-positive metastatic TNBC (mTNBC)
Key research findings guiding the optimal use of PARP inhibitors for patients with mBC
Primary results from the Phase III TROPiCS-02 study evaluating sacituzumab govitecan versus treatment of physician’s choice for patients with ER-positive advanced breast cancer
Other novel agents under investigation for mTNBC (eg, T-DXd, ladiratuzumab vedotin, datopotamab deruxtecan)

Module 2
Genitourinary Cancers | 10:05 AM – 11:05 AM PT (1:05 PM – 2:05 PM ET)

Major efficacy and safety findings with and current clinical role of the oral GnRH antagonist relugolix for men with advanced prostate cancer
Key findings from the STAMPEDE platform assessing the addition of abiraterone and prednisolone with or without enzalutamide to androgen deprivation therapy (ADT) for men with high-risk nonmetastatic prostate cancer
Long-term efficacy outcomes with enzalutamide, apalutamide or darolutamide for nonmetastatic castration-resistant prostate cancer; implications of differential toxicity profiles for therapeutic selection
PEACE-1 trial: Docetaxel with or without abiraterone with or without local radiation therapy for men with de novo metastatic hormone-sensitive prostate cancer (mHSPC); implications for clinical practice
Long-term follow-up from Phase III studies supporting the use of enzalutamide and apalutamide for mHSPC
Results from the Phase III ARASENS trial demonstrating improved overall survival with darolutamide in combination with docetaxel and ADT for mHSPC; potential clinical significance
Efficacy and safety of approved PARP inhibitors (olaparib and rucaparib) in men with metastatic castration-resistant prostate cancer (mCRPC); optimal integration of these agents into management algorithms
Efficacy and safety findings from the Phase III PROpel trial comparing olaparib in combination with abiraterone to abiraterone alone as first-line therapy for patients with mCRPC with and without homologous recombination repair (HRR) gene mutations
First results of the Phase III MAGNITUDE study of niraparib with abiraterone/prednisone as first-line therapy for patients with mCRPC with and without HRR gene mutations
Other ongoing Phase III clinical research evaluating the role of PARP inhibitors with secondary hormonal agents for patients with mCRPC (eg, TALAPRO-2, CASPAR) and mHSPC (eg, TALAPRO-3, AMPLITUDE)
Available results from studies investigating the optimal sequencing of cabazitaxel in therapy for mCRPC
Impact of the addition of bone-protecting agents during treatment with radium-223 chloride and enzalutamide in the Phase III EORTC-1333-GUCG/PEACE III trial
Findings from the Phase III VISION study evaluating ¹⁷⁷Lu-PSMA-617 for progressive PSMA-positive mCRPC; recent FDA approval and appropriate integration into clinical practice
Three-year follow-up results from the TheraP trial evaluating ¹⁷⁷Lu-PSMA-617 versus cabazitaxel for mCRPC progressing after docetaxel
Findings from the Phase III KEYNOTE-564 study of adjuvant pembrolizumab for high-risk clear-cell renal cell carcinoma (RCC); recent FDA approval and patient selection
Use of nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib for treatment-naïve metastatic RCC (mRCC)
FDA approval for lenvatinib/pembrolizumab as first-line therapy for mRCC
Results of the Phase III CheckMate 9ER trial of nivolumab/cabozantinib for previously untreated mRCC; FDA approval and optimal integration into current first-line treatment algorithms
Rational sequencing of available therapies for RCC that progresses on front-line treatment; patient-specific factors in decision-making in this setting
FDA approval and optimal clinical role of tivozanib for patients with mRCC
FDA approval, ongoing evaluation and efficacy of belzutifan in patients with von Hippel-Lindau disease-associated RCC
Selection of appropriate patients with high-risk non-muscle-invasive urothelial bladder cancer (UBC) for pembrolizumab therapy
Results of the Phase III CheckMate 274 trial comparing nivolumab to placebo after surgery for patients with high-risk muscle-invasive UBC; recent FDA approval and optimal integration into practice
Efficacy, tolerability and ongoing investigation of TAR-200 (intravesical gemcitabine drug delivery system) for muscle-invasive UBC
Findings from the Phase II TRUCE-02 trial of tislelizumab combined with nab paclitaxel for high-risk non-muscle-invasive UBC
Current clinical role of atezolizumab and pembrolizumab as first-line treatment for metastatic UBC (mUBC); importance of chemotherapy eligibility and PD-L1 status in patient selection for this strategy
Appropriate incorporation of first-line maintenance avelumab into clinical care
Activity of enfortumab vedotin in patients with progressive mUBC; FDA-approved indication and optimal integration into the treatment paradigm
Efficacy and potential clinical role of enfortumab vedotin/pembrolizumab for patients with previously untreated mUBC
Clinical role of erdafitinib for patients with mUBC and FGFR3 or FGFR2 genetic alterations
Findings from the Phase II TROPHY U-01 trial leading to the FDA approval of sacituzumab govitecan for patients with progressive mUBC; optimal integration into clinical management
FDA breakthrough therapy designation for disitamab vedotin for progressive HER2-overexpressing mUBC

Break | 11:05 AM – 11:20 AM PT (2:05 PM – 2:20 PM ET)

Module 3
Multiple Myeloma (MM) | 11:20 AM – 12:20 PM PT (2:20 PM – 3:20 PM ET)

Current utility of carfilzomib as a component of up-front therapy
Published research findings with daratumumab-containing front-line regimens for newly diagnosed MM; role for patients who are eligible and ineligible for transplant
Recently presented findings from the Phase III DETERMINATION trial of RVD (lenalidomide/bortezomib/dexamethasone), with or without autologous stem cell transplant, and maintenance lenalidomide to disease progression for patients with newly diagnosed MM; implications for clinical practice
Current role of minimal residual disease (MRD) assessment in MM decision-making; optimal platforms
Approach to maintenance therapy for transplant-eligible and ineligible patients, including those who have received daratumumab-based induction therapy
Available data with and current indications, if any, for ixazomib in the induction and maintenance settings
FDA approval of idecabtagene vicleucel and updated results from the pivotal Phase II KarMMa trial evaluating this agent for patients with relapsed/refractory (R/R) MM
Available data from the CARTITUDE-1 and CARTITUDE-2 studies of ciltacabtagene autoleucel for pretreated MM; recent FDA approval and clinical role
Early data with and ongoing research evaluating other chimeric antigen receptor (CAR) T-cell platforms and strategies for MM
Incidence, severity and management of class-effect toxicities observed with B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies
Published Phase III research with isatuximab for R/R MM (eg, ICARIA-MM, IKEMA trials)
Results from the Phase III BOSTON trial evaluating selinexor in combination with bortezomib/dexamethasone for R/R MM; FDA approval and patient selection
Ongoing studies of selinexor in combination with other agents and in earlier lines of therapy
Efficacy and safety results from the Phase II DREAMM-2 study leading to the FDA approval of belantamab mafodotin monotherapy for patients with R/R MM; incorporation into routine practice
Monitoring for and management of ocular and other toxicities with belantamab mafodotin
Available data with and ongoing evaluation of belantamab mafodotin in combination with other systemic therapies
Mechanism of action of and available safety and efficacy data with BCMA-directed (eg, teclistamab, elranatamab) and non-BCMA-directed (eg, talquetamab, cevostamab) bispecific antibodies for R/R MM
Biologic rationale for targeting Bcl-2 in MM; published data with and ongoing investigation of venetoclax-based therapy for patients with t(11;14) MM or Bcl-2 overexpression
Activity and safety observed with the cereblon E3 ligase modulators iberdomide and CC-92480 in patients with heavily pretreated MM
Other promising novel agents and strategies under investigation for MM

Lunch Break | 12:20 PM – 12:55 PM PT (3:20 PM – 3:55 PM ET)

Module 4
Chronic Lymphocytic Leukemia (CLL) and Lymphomas | 12:55 PM – 1:55 PM PT (3:55 PM – 4:55 PM ET)

Pivotal data sets with Bruton tyrosine kinase (BTK) inhibitor-based therapy for treatment-naïve CLL
Implications for therapeutic decision-making of results from the Phase III ELEVATE-RR study evaluating acalabrutinib versus ibrutinib for previously treated high-risk CLL
Results from the Phase III ALPINE and SEQUOIA trials evaluating zanubrutinib for CLL
Key data sets informing the optimal use of venetoclax for newly diagnosed CLL
Current role and optimal platforms for MRD assessment for patients with CLL
Results from the Phase III GLOW trial evaluating first-line ibrutinib/venetoclax versus chlorambucil/obinutuzumab
Key factors guiding the selection of therapy for patients with disease progression on first-line treatment
Current and future role of PI3 kinase (PI3K) inhibition in the CLL treatment paradigm
Efficacy and safety of pirtobrutinib in the Phase I/II BRUIN study; ongoing investigation and potential clinical role of CD19-directed CAR T-cell therapy for patients with R/R CLL
Integration of obinutuzumab into current therapeutic algorithms for treatment-naïve and R/R follicular lymphoma (FL)
Lenalidomide/rituximab in the management of newly diagnosed and R/R FL
Key findings from the Phase III CHRONOS-3 trial of copanlisib in combination with rituximab for patients with R/R FL
Available data from the Phase IIb UNITY-NHL trial evaluating umbralisib for patients with R/R FL; FDA approval of umbralisib
Results from the Phase II CITADEL-203 study evaluating the next-generation PI3K inhibitor parsaclisib for R/R FL
Optimal integration of tazemetostat into the management of previously treated FL with and without EZH2 mutations
Available data with and FDA approvals of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tis-cel) for R/R FL
Early-phase data with and potential clinical role of investigational bispecific antibodies (eg, mosunetuzumab, glofitamab, epcoritamab) for R/R FL
Key results from the Phase III POLARIX study comparing polatuzumab vedotin in combination with chemotherapy to R-CHOP for previously untreated diffuse large B-cell lymphoma (DLBCL); implications for clinical practice
Published research findings with polatuzumab vedotin in combination with bendamustine/rituximab (BR) for R/R DLBCL
Available data with and FDA approval of loncastuximab tesirine
Key data leading to the FDA approval of tafasitamab/lenalidomide for R/R DLBCL
Long-term data with axi-cel, tis-cel and lisocabtagene maraleucel (liso-cel) for R/R DLBCL
Phase III data with CAR T-cell therapy as second-line treatment for DLBCL
Research database supporting the FDA approvals of ibrutinib, acalabrutinib and zanubrutinib for R/R mantle cell lymphoma (MCL); key factors in the choice of BTK inhibitor and practical use of these agents
Primary results from the Phase III SHINE study of ibrutinib/BR and maintenance rituximab as first-line treatment for older patients with MCL
Activity and safety data with and ongoing Phase III investigations of novel agents (eg, lenalidomide, BTK inhibitors) for previously untreated MCL
Venetoclax alone or combined with other agents (eg, BTK inhibitors) for MCL
Key efficacy and safety data with approved (brexucabtagene autoleucel) and investigational (liso-cel) CAR T-cell platforms in therapy for MCL
Efficacy and safety observed with pirtobrutinib in patients with MCL in the Phase I/II BRUIN trial
Long-term progression-free survival follow-up and prespecified overall survival analysis from the Phase III ECHELON-1 trial of first-line brentuximab vedotin (BV) and AVD (doxorubicin/vinblastine/dacarbazine) for advanced classical Hodgkin lymphoma
Early findings with BV combined with chemotherapy for early-stage unfavorable-risk Hodgkin lymphoma
Current role of BV for older patients with newly diagnosed Hodgkin lymphoma
Potential role of BV alone or in combination with immune checkpoint inhibition as a bridge to transplant
Key outcomes from the Phase III KEYNOTE-204 trial evaluating pembrolizumab versus BV for patients with R/R Hodgkin lymphoma; implications for clinical practice

Module 5
Gastrointestinal Cancers | 1:55 PM – 2:55 PM PT (4:55 PM – 5:55 PM ET)

Appropriate use of encorafenib/cetuximab for patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutations; available results and ongoing investigation with earlier use of BRAF-targeted therapy
Immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient mCRC
Incorporation of regorafenib and TAS-102 in the treatment of multiregimen-refractory mCRC
Available data with and potential role of TAS-102 in combination with other systemic agents or in earlier disease stages; NCCN guideline inclusion of TAS-102/bevacizumab
Updated results from the DESTINY-CRC01 study of T-DXd for HER2-expressing mCRC
Early results with and ongoing evaluation of the KRAS G12C inhibitor sotorasib for mCRC with a KRAS G12C mutation
Phase III data (eg, from the CheckMate 649, CheckMate 648 and KEYNOTE-590 trials) demonstrating the efficacy and safety of first-line checkpoint inhibitor-containing regimens for advanced gastric, gastroesophageal junction (GEJ) and esophageal cancer
Available Phase III research findings (eg, from the ORIENT-16, ORIENT-15 and JUPITER-06 trials) with investigational anti-PD-1 antibodies in combination with chemotherapy as first-line treatment for advanced gastroesophageal tumors; potential clinical role
Available data from the Phase III CheckMate 577 study of adjuvant nivolumab for resected esophageal or GEJ cancer
Optimal placement of ramucirumab in current clinical algorithms for metastatic gastric/GEJ cancer; ongoing investigation of ramucirumab-containing combination regimens
Use of TAS-102 in the management of heavily pretreated metastatic gastric/GEJ cancer
Principal outcomes in the Phase III KEYNOTE-811 trial evaluating first-line pembrolizumab/ trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
DESTINY-Gastric01 and DESTINY-Gastric02 trials of T-DXd for progressive HER2-positive gastric/GEJ cancer
Key findings from the Phase II FIGHT trial of first-line bemarituzumab/chemotherapy for FGFR2b-positive metastatic gastric/GEJ cancer
Key data with first-line atezolizumab/bevacizumab for unresectable hepatocellular carcinoma (HCC)
Recently presented findings from the Phase III HIMALAYA trial evaluating first-line durvalumab/tremelimumab for unresectable HCC
Results from the Phase III COSMIC-312 study evaluating first-line cabozantinib/atezolizumab versus sorafenib for metastatic HCC
Roles of sorafenib and lenvatinib in first-line therapy for advanced HCC
Long-term outcomes with anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) for progressive HCC
Results from the TOPAZ-1 trial of first-line durvalumab with chemotherapy for advanced biliary tract cancers
Outcomes from the Phase II HERB study of T-DXd for patients with HER2-expressing unresectable or recurrent biliary tract cancer
FDA approvals of pemigatinib and infigratinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
Results with futibatinib for intrahepatic cholangiocarcinoma with an FGFR2 fusion/rearrangement from the FOENIX-CCA2 trial
FDA approval of ivosidenib for patients with previously treated cholangiocarcinoma with an IDH1 mutation; implications for current practice
Selection of neoadjuvant and adjuvant systemic therapy for patients with localized pancreatic adenocarcinoma (PAD)
Optimal selection of first- and later-line treatment for patients with metastatic PAD
Patient selection for and practical integration of nal-IRI for relapsed metastatic PAD; early front-line activity observed with NALIRIFOX, the combination of nal-IRI, 5-FU/leucovorin and oxaliplatin
Key efficacy and safety findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for patients with metastatic PAD with a germline BRCA mutation

Break | 2:55 PM – 3:10 PM PT (5:55 PM – 6:10 PM ET)

Module 6
Lung Cancer | 3:10 PM – 4:10 PM PT (6:10 PM – 7:10 PM ET)

FDA approval of adjuvant osimertinib; patient selection and optimal incorporation into clinical care
Optimal first-line treatment for metastatic non-small cell lung cancer (NSCLC) with EGFR tumor mutations
Available data with and ongoing evaluation of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan for metastatic EGFR tyrosine kinase inhibitor-resistant NSCLC
Key data informing the FDA approvals of mobocertinib and amivantamab for patients with EGFR exon 20 insertion mutations who have experienced disease progression on first-line chemotherapy
Activity and tolerability of lazertinib and amivantamab in the CHRYSALIS-2 trial for patients with NSCLC with EGFR mutations after disease progression on osimertinib and platinum-based chemotherapy
Available data informing the use of alectinib, brigatinib or lorlatinib as first-line therapy for patients with NSCLC and ALK rearrangements
Principal efficacy and safety results with entrectinib for NSCLC with a ROS1 rearrangement; appropriate integration into clinical practice
Published data with and ongoing trials of other “next-generation” ROS1 inhibitors (eg, repotrectinib, larotrectinib, lorlatinib, ceritinib)
Available data with selpercatinib and with pralsetinib for patients with advanced NSCLC and RET alterations; optimal integration into clinical practice
Current clinical roles of capmatinib and tepotinib for NSCLC with a MET exon 14 mutation
Principal efficacy and safety findings with sotorasib for pretreated NSCLC with a KRAS G12C mutation
Key outcomes from the Phase II DESTINY-Lung01 study evaluating T-DXd in NSCLC with a HER2 mutation; FDA priority review designation and potential nonresearch role
Results from the Phase III CheckMate 816 trial evaluating neoadjuvant nivolumab in combination with chemotherapy for resectable NSCLC
FDA approval and current clinical role of adjuvant atezolizumab; principal findings from the Phase III IMpower010 trial evaluating atezolizumab after adjuvant chemotherapy for patients with completely resected NSCLC
Long-term data from the Phase III PACIFIC trial of consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC
Other ongoing and planned clinical trials of immune checkpoint inhibitors for patients with nonmetastatic NSCLC
Clinical trial database supporting the FDA approvals of pembrolizumab and atezolizumab as monotherapy and combined with chemotherapy as first-line treatment
Available efficacy and safety data with cemiplimab as monotherapy and in combination with platinum-based chemotherapy as first-line treatment for NSCLC
Phase III clinical trial results with first-line nivolumab/ipilimumab with and without chemotherapy (CheckMate 227, CheckMate 9LA); patient selection and optimal integration into practice
POSEIDON: A Phase III trial evaluating durvalumab or durvalumab/tremelimumab in combination with platinum-based chemotherapy versus chemotherapy alone as first-line therapy
Efficacy and safety observed with the anti-PD-1 monoclonal antibody tislelizumab in patients with advanced NSCLC; ongoing evaluation
Ongoing investigation of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan for patients with progressive metastatic NSCLC
Key efficacy and safety findings with chemotherapy in combination with atezolizumab or durvalumab for previously untreated extensive-stage small cell lung cancer (SCLC)
Available data with and current clinical role of lurbinectedin for patients with SCLC who experience disease progression after platinum-based therapy
FDA approval of trilaciclib; optimal incorporation into routine practice as a means to preserve bone marrow function during chemotherapy in patients with extensive-stage SCLC

Closing Remarks | 4:10 PM – 4:30 PM PT (7:10 PM – 7:30 PM ET)

MEETING ADJOURNS | 4:30 PM PT (7:30 PM ET)